Skip to main content
NASDAQ:UG

United-Guardian Competitors

$15.07
+0.52 (+3.57 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.72
$15.80
50-Day Range
$14.40
$15.45
52-Week Range
$13.18
$18.30
Volume26,997 shs
Average Volume6,993 shs
Market Capitalization$69.17 million
P/E Ratio16.74
Dividend Yield4.95%
Beta0.02

Competitors

United-Guardian (NASDAQ:UG) Vs. FREQ, ALPN, EIGR, IMPL, BLU, and NH

Should you be buying UG stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to United-Guardian, including Frequency Therapeutics (FREQ), Alpine Immune Sciences (ALPN), Eiger BioPharmaceuticals (EIGR), Impel NeuroPharma (IMPL), BELLUS Health (BLU), and NantHealth (NH).

Frequency Therapeutics (NASDAQ:FREQ) and United-Guardian (NASDAQ:UG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares Frequency Therapeutics and United-Guardian's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Frequency Therapeutics$28.95 million9.52$-18,750,000.00($2.29)-3.52
United-Guardian$13.60 million5.09$4.76 millionN/AN/A

United-Guardian has lower revenue, but higher earnings than Frequency Therapeutics.

Risk & Volatility

Frequency Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, United-Guardian has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500.

Insider & Institutional Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. Comparatively, 26.1% of United-Guardian shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by company insiders. Comparatively, 29.5% of United-Guardian shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Frequency Therapeutics and United-Guardian's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Frequency Therapeutics-68.59%-12.56%-9.92%
United-Guardian32.85%37.02%31.83%

Analyst Recommendations

This is a breakdown of recent recommendations for Frequency Therapeutics and United-Guardian, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Frequency Therapeutics00303.00
United-Guardian0000N/A

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 359.63%. Given Frequency Therapeutics' higher possible upside, equities analysts clearly believe Frequency Therapeutics is more favorable than United-Guardian.

United-Guardian (NASDAQ:UG) and Alpine Immune Sciences (NASDAQ:ALPN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and Alpine Immune Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$13.60 million5.09$4.76 millionN/AN/A
Alpine Immune Sciences$1.74 million157.67$-41,850,000.00($2.28)-5.04

United-Guardian has higher revenue and earnings than Alpine Immune Sciences.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 52.9% of Alpine Immune Sciences shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 76.1% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and Alpine Immune Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United-Guardian32.85%37.02%31.83%
Alpine Immune Sciences-606.16%-80.38%-30.76%

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and Alpine Immune Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United-Guardian0000N/A
Alpine Immune Sciences00603.00

Alpine Immune Sciences has a consensus price target of $19.40, suggesting a potential upside of 68.99%. Given Alpine Immune Sciences' higher possible upside, analysts plainly believe Alpine Immune Sciences is more favorable than United-Guardian.

United-Guardian (NASDAQ:UG) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and Eiger BioPharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$13.60 million5.09$4.76 millionN/AN/A
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-2.61

United-Guardian has higher revenue and earnings than Eiger BioPharmaceuticals.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 68.8% of Eiger BioPharmaceuticals shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 5.8% of Eiger BioPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and Eiger BioPharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United-Guardian32.85%37.02%31.83%
Eiger BioPharmaceuticalsN/A-100.60%-57.76%

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and Eiger BioPharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United-Guardian0000N/A
Eiger BioPharmaceuticals00203.00

Eiger BioPharmaceuticals has a consensus price target of $25.50, suggesting a potential upside of 217.56%. Given Eiger BioPharmaceuticals' higher possible upside, analysts plainly believe Eiger BioPharmaceuticals is more favorable than United-Guardian.

Summary

United-Guardian beats Eiger BioPharmaceuticals on 7 of the 11 factors compared between the two stocks.

United-Guardian (NASDAQ:UG) and Impel NeuroPharma (NASDAQ:IMPL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and Impel NeuroPharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$13.60 million5.09$4.76 millionN/AN/A
Impel NeuroPharmaN/AN/AN/AN/AN/A

United-Guardian has higher revenue and earnings than Impel NeuroPharma.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and Impel NeuroPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United-Guardian32.85%37.02%31.83%
Impel NeuroPharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and Impel NeuroPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United-Guardian0000N/A
Impel NeuroPharma0000N/A

Summary

United-Guardian beats Impel NeuroPharma on 6 of the 6 factors compared between the two stocks.

United-Guardian (NASDAQ:UG) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and BELLUS Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$13.60 million5.09$4.76 millionN/AN/A
BELLUS Health$30,000.009,008.76$-25,970,000.00($0.55)-6.27

United-Guardian has higher revenue and earnings than BELLUS Health.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 38.4% of BELLUS Health shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 24.2% of BELLUS Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United-Guardian32.85%37.02%31.83%
BELLUS Health-190,199.98%-30.46%-28.77%

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and BELLUS Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United-Guardian0000N/A
BELLUS Health02602.75

BELLUS Health has a consensus price target of $8.6167, suggesting a potential upside of 149.76%. Given BELLUS Health's higher possible upside, analysts plainly believe BELLUS Health is more favorable than United-Guardian.

Summary

United-Guardian beats BELLUS Health on 7 of the 12 factors compared between the two stocks.

United-Guardian (NASDAQ:UG) and NantHealth (NASDAQ:NH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and NantHealth's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$13.60 million5.09$4.76 millionN/AN/A
NantHealth$95.96 million2.66$-62,760,000.00($0.57)-3.95

United-Guardian has higher earnings, but lower revenue than NantHealth.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, NantHealth has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 5.5% of NantHealth shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 59.6% of NantHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and NantHealth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United-Guardian32.85%37.02%31.83%
NantHealth-60.94%N/A-32.31%

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and NantHealth, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United-Guardian0000N/A
NantHealth0000N/A

Summary

United-Guardian beats NantHealth on 7 of the 10 factors compared between the two stocks.


United-Guardian Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$8.05+25.5%$275.46 million$28.95 million-11.50News Coverage
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.48+1.0%$274.34 million$1.74 million-7.97Earnings Announcement
News Coverage
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.03+0.7%$272.63 millionN/A-3.30Analyst Report
Analyst Revision
IMPL
Impel NeuroPharma
0.3$13.95+2.4%$270.84 millionN/A0.00
BELLUS Health logo
BLU
BELLUS Health
1.7$3.45+1.2%$270.26 million$30,000.00-5.85Earnings Announcement
NantHealth logo
NH
NantHealth
1.0$2.25+5.8%$255.15 million$95.96 million-5.11
EyePoint Pharmaceuticals logo
EYPT
EyePoint Pharmaceuticals
1.4$8.86+0.5%$254.65 million$20.36 million-2.61Analyst Downgrade
Kamada logo
KMDA
Kamada
1.4$5.67+3.4%$252.43 million$127.19 million11.81Earnings Announcement
Talis Biomedical logo
TLIS
Talis Biomedical
1.7$9.77+12.9%$250.48 millionN/A0.00Analyst Report
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.15+4.3%$247.61 millionN/A-4.12Earnings Announcement
News Coverage
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$5.82+9.3%$247.46 millionN/A-2.30
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$4.98+2.0%$245.86 million$2.42 million-4.37Analyst Downgrade
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$2.50+8.8%$240.97 million$6.01 million-2.03
Galectin Therapeutics logo
GALT
Galectin Therapeutics
1.4$4.21+1.4%$240.63 millionN/A-10.79Upcoming Earnings
Trevena logo
TRVN
Trevena
1.3$1.46+3.4%$238.85 million$30,000.00-6.35Analyst Upgrade
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$1.89+10.6%$237.73 millionN/A0.00Earnings Announcement
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$2.66+6.0%$235.80 million$3.05 million-3.75Earnings Announcement
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$11.45+13.2%$233.47 million$22.90 million-8.61News Coverage
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.26+3.5%$233.40 millionN/A-2.27Earnings Announcement
Tricida logo
TCDA
Tricida
1.9$4.64+6.3%$233.27 millionN/A-0.86
Chiasma logo
CHMA
Chiasma
1.6$4.02+3.2%$232.73 millionN/A-2.77
Mustang Bio logo
MBIO
Mustang Bio
1.6$2.70+6.3%$229.97 millionN/A-2.16Upcoming Earnings
Lucira Health logo
LHDX
Lucira Health
1.0$5.96+23.2%$229.67 millionN/A0.00High Trading Volume
Unusual Options Activity
Gap Down
TLC
Taiwan Liposome
1.2$5.45+9.7%$229.32 million$6.99 million-6.81Gap Up
VINC
Vincerx Pharma
1.0$16.34+1.0%$228.50 millionN/A0.00
Harrow Health logo
HROW
Harrow Health
1.4$8.79+3.3%$228.40 million$51.17 million-109.88Earnings Announcement
Analyst Report
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.05+4.8%$226.87 millionN/A0.00Upcoming Earnings
PLx Pharma logo
PLXP
PLx Pharma
1.5$9.80+0.0%$223.83 million$570,000.00-7.97
Immutep logo
IMMP
Immutep
1.3$3.45+4.6%$223.81 million$4.92 million0.00
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.30+6.1%$223.70 millionN/A-2.34Earnings Announcement
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.2$6.47+3.1%$222.32 million$28.80 million-4.17Earnings Announcement
Analyst Revision
NextCure logo
NXTC
NextCure
1.6$8.01+0.1%$221.16 million$6.35 million-7.09Analyst Upgrade
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$8.78+8.0%$218.87 millionN/A-6.41
Sierra Oncology logo
SRRA
Sierra Oncology
1.8$17.56+6.2%$216.87 millionN/A-1.26Gap Down
DarioHealth logo
DRIO
DarioHealth
1.3$13.90+9.0%$215.10 million$7.56 million-1.74Upcoming Earnings
Gap Up
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$8.48+7.3%$215.09 millionN/A-3.21Earnings Announcement
Analyst Upgrade
News Coverage
Cerecor logo
CERC
Cerecor
1.8$2.25+4.9%$214.78 million$6.75 million-7.50Earnings Announcement
Nemaura Medical logo
NMRD
Nemaura Medical
0.2$9.24+8.9%$211.87 millionN/A-46.20
Akumin logo
AKU
Akumin
0.6$2.95+1.7%$209.90 millionN/A0.00
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$7.16+2.1%$205.25 million$220,000.008.84
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
1.7$4.90+9.0%$202.70 million$54.64 million-2.22Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Mereo BioPharma Group logo
MREO
Mereo BioPharma Group
1.5$2.98+10.7%$202.02 millionN/A-1.20Analyst Report
CTI BioPharma logo
CTIC
CTI BioPharma
1.7$2.16+2.3%$201.49 million$3.35 million-3.18Analyst Report
Lannett logo
LCI
Lannett
2.1$4.85+9.9%$201.01 million$545.74 million-6.74
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.42+2.1%$198.51 million$4.13 million-3.16News Coverage
Gap Up
Edap Tms logo
EDAP
Edap Tms
1.3$5.93+5.6%$197.56 million$50.23 million-98.83Earnings Announcement
High Trading Volume
MediciNova logo
MNOV
MediciNova
1.2$4.05+3.0%$197.51 millionN/A0.00
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.62+3.1%$196.47 million$29.35 million-1.88Earnings Announcement
RPHM
Reneo Pharmaceuticals
2.0$8.01+39.2%$193.93 millionN/A0.00Quiet Period Expiration
Osmotica Pharmaceuticals logo
OSMT
Osmotica Pharmaceuticals
1.1$3.07+2.9%$192.14 million$240.03 million-3.34
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.